Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GT801 Injection in Adult Patients With Relapsed/Refractory CD19-positive B-cell Hematologic Malignancies and Autoimmune Hemolytic Anemia
NCT07205315Phase 1Recruiting
- Sponsor
- Grit Biotechnology
- Start
- Sep 2025
- Primary completion
- Nov 2027
- Modality
- CAR-T Cells, Lipid-based Nanoparticles, mRNA Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of GT801 in B cell acute lymphoblastic leukemia (B-ALL), chronic lymphocytic leukemia (CLL), B-cell non-Hodgkin lymphoma (B-NHL) and 1 more, sponsored by Grit Biotechnology. Primary endpoints: Dose Limiting Toxicity at 28 days and Adverse Events at 3 months. Started Sep 2025; status: recruiting.
02
Drugs
GT801
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)chronic lymphocytic leukemia (CLL)B-cell non-Hodgkin lymphoma (B-NHL)autoimmune hemolytic anemia (AIHA)
Beyond the preview
Go deeper on NCT07205315.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07205315.